Early Diagnosis and Current Status of Immunotherapy for Thymic Carcinoma
These findings underscore the transformative potential of chemo-immunotherapy as a first-line option for advanced TC, while also highlighting persistent challenges: the absence of validated predictive biomarkers, the limited efficacy of ICI monotherapy, and the lack of large-scale randomized controlled evidence.